Cipla Limited
Valuation (87/100) does the heavy lifting; financial trend (8/100) is the drag.
Buy zoneCipla Limited earns a Buy from StocksWizard, with a blended score of 61/100. At ₹1,473.2 it trades below our blended DCF and relative-multiples fair value of ₹1,915.97, about 30% upside to that estimate — we read it as undervalued by 30%. On 30.0x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 11% below its 52-week high of ₹1,648.14 and 25% above the low of ₹1,181.32. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9. The average analyst target of ₹1,456.73 implies about 1% downside across 37 analysts. It clears 9 of 13 investability checks, with durability 58, valuation 74 and momentum 77 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,532.78.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-10.61% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy61Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 11.7%
- Pass: Low debt (D/E < 0.5): 0.02x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -2%
- Fail: Earnings growing: -55%
- Pass: Net margin ≥ 10%: 13.9%
- Pass: Current ratio > 1.5: 3.44
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 10.81
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter34.6%
- Institutions44.4%
- Public & other21.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 10.81.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~30% below our estimated fair value.
Bear case
Weaknesses
- Weak Piotroski score (3/9).
Threats
- Earnings contracting year on year.
About Cipla Limited
Cipla Limited manufactures and distributes pharmaceutical products across India, the United States, South Africa, and internationally. The company produces generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations targeting therapeutic areas including cardiovascular disease, pulmonary conditions, kidney disorders, neurodegenerative diseases, hypertension, and metabolic disorders.
Cipla Limited — frequently asked questions
Is Cipla Limited a buy, hold or sell?
StocksWizard currently rates Cipla Limited (CIPLA) a Buy, based on a blended score of 61/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Cipla Limited's fair value?
Our blended DCF and relative-valuation model estimates Cipla Limited's fair value at about ₹1,915.97, versus a current price of ₹1,473.2 — roughly 30% upside. On that basis the stock looks undervalued by 30%.
Is Cipla Limited financially healthy?
Cipla Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 3/9.
How has Cipla Limited's share price performed?
Cipla Limited is up 11% over three months, and last traded at ₹1,473.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.